Literature DB >> 16972044

Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling.

M Möhlig1, A Flöter, J Spranger, M O Weickert, T Schill, H W Schlösser, G Brabant, A F H Pfeiffer, J Selbig, C Schöfl.   

Abstract

AIMS/HYPOTHESIS: Polycystic ovary syndrome (PCOS) is a risk factor of type 2 diabetes. Screening for impaired glucose metabolism (IGM) with an OGTT has been recommended, but this is relatively time-consuming and inconvenient. Thus, a strategy that could minimise the need for an OGTT would be beneficial.
MATERIALS AND METHODS: Consecutive PCOS patients (n=118) with fasting glucose <6.1 mmol/l were included in the study. Parameters derived from medical history, clinical examination and fasting blood samples were assessed by decision tree modelling for their ability to discriminate women with IGM (2-h OGTT value >/=7.8 mmol/l) from those with NGT.
RESULTS: According to the OGTT results, 93 PCOS women had NGT and 25 had IGM. The best decision tree consisted of HOMA-IR, the proinsulin:insulin ratio, proinsulin, 17-OH progesterone and the ratio of luteinising hormone:follicle-stimulating hormone. This tree identified 69 women with NGT. The remaining 49 women included all women with IGM (100% sensitivity, 74% specificity to detect IGM). Pruning this tree to three levels still identified 53 women with NGT (100% sensitivity, 57% specificity to detect IGM). Restricting the data matrix used for tree modelling to medical history and clinical parameters produced a tree using BMI, waist circumference and WHR. Pruning this tree to two levels separated 27 women with NGT (100% sensitivity, 29% specificity to detect IGM). The validity of both trees was tested by a leave-10%-out cross-validation. CONCLUSIONS/
INTERPRETATION: Decision trees are useful tools for separating PCOS women with NGT from those with IGM. They can be used for stratifying the metabolic screening of PCOS women, whereby the number of OGTTs can be markedly reduced.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16972044     DOI: 10.1007/s00125-006-0395-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  42 in total

1.  Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome.

Authors:  Mark R Palmert; Catherine M Gordon; Alex I Kartashov; Richard S Legro; S Jean Emans; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

Review 2.  Polycystic ovary syndrome.

Authors:  S Franks
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

3.  Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.

Authors:  R J Norman; L Masters; C R Milner; J X Wang; M J Davies
Journal:  Hum Reprod       Date:  2001-09       Impact factor: 6.918

4.  Improved detection of prostate cancer using classification and regression tree analysis.

Authors:  Mark Garzotto; Tomasz M Beer; R Guy Hudson; Laura Peters; Yi-Ching Hsieh; Eduardo Barrera; Thomas Klein; Motomi Mori
Journal:  J Clin Oncol       Date:  2005-03-21       Impact factor: 44.544

Review 5.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors:  A Dunaif
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

6.  Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome.

Authors:  Joachim Spranger; Matthias Möhlig; Uta Wegewitz; Michael Ristow; Andreas F H Pfeiffer; Thilo Schill; Hans W Schlösser; Georg Brabant; Christof Schöfl
Journal:  Clin Endocrinol (Oxf)       Date:  2004-12       Impact factor: 3.478

7.  The polycystic ovary syndrome per se is not associated with increased chronic inflammation.

Authors:  Matthias Möhlig; Joachim Spranger; Martin Osterhoff; Michael Ristow; Andreas F H Pfeiffer; Thilo Schill; Hans W Schlösser; Georg Brabant; Christof Schöfl
Journal:  Eur J Endocrinol       Date:  2004-04       Impact factor: 6.664

8.  Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women.

Authors:  H F Escobar-Morreale; G Villuendas; J I Botella-Carretero; J Sancho; J L San Millán
Journal:  Diabetologia       Date:  2003-05-09       Impact factor: 10.122

Review 9.  Hyperinsulinaemia is a predictor of non-insulin-dependent diabetes mellitus.

Authors:  P Zimmet; G Dowse; P Bennett
Journal:  Diabete Metab       Date:  1991-05

10.  Genomic data sampling and its effect on classification performance assessment.

Authors:  Francisco Azuaje
Journal:  BMC Bioinformatics       Date:  2003-01-28       Impact factor: 3.169

View more
  4 in total

1.  A reverse postural test as a screening tool for aldosterone-producing adenoma: a pilot study.

Authors:  Martin O Weickert; Beate Schöfl-Siegert; Ayman M Arafat; Andreas F H Pfeiffer; Matthias Möhlig; Christof Schöfl
Journal:  Endocrine       Date:  2009-04-28       Impact factor: 3.633

2.  The Usefulness of Homeostatic Measurement Assessment-Insulin Resistance (HOMA-IR) for Detection of Glucose Intolerance in Thai Women of Reproductive Age with Polycystic Ovary Syndrome.

Authors:  Thanyarat Wongwananuruk; Manee Rattanachaiyanont; Pichai Leerasiri; Suchada Indhavivadhana; Kitirat Techatraisak; Surasak Angsuwathana; Prasong Tanmahasamut; Chongdee Dangrat
Journal:  Int J Endocrinol       Date:  2012-04-24       Impact factor: 3.257

Review 3.  Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review.

Authors:  Sarantis Livadas; Panagiotis Anagnostis; Julia K Bosdou; Dimitra Bantouna; Rodis Paparodis
Journal:  World J Diabetes       Date:  2022-01-15

4.  Can dysglycemia in OGTT be predicted by baseline parameters in patients with PCOS?

Authors:  Sarantis Livadas; Christina Bothou; Justyna Kuliczkowska-Płaksej; Ralitsa Robeva; Andromahi Vryonidou; Jelica Bjekic Macut; Ioannis Androulakis; Milica Opalic; Zadalla Mouslech; Andrej Milewicz; Alessandra Gambineri; Dimitrios Panidis; Djuro Macut
Journal:  Endocr Connect       Date:  2022-04-22       Impact factor: 3.221

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.